23 December, 2025

Australia
Australia develops new antimalarial drug candidate to address growing challenge of drug resistance

Researchers in Australia have developed a new antimalarial drug candidate designed to address the growing challenge of d...Read more

- 22 December 2025 News

China
China’s Jacobio inks immuno-oncology deal worth $1.9 B with AstraZeneca

China-based Jacobio Pharma has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73.&n...Read more

- 22 December 2025 News


North America
Korea's Samsung Biologics expands US manufacturing capabilities after acquiring Human Genome Sciences from GSK


South Korea-based Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has announced...Read more

- 22 December 2025 News


Japan
Japan's Chitose and Fujifilm Biosciences partner to drive global innovation and biopharma manufacturing


Japan-based Chitose Laboratory Corp. and Fujifilm Biosciences Inc. have announced a new strategic alliance that leverage...Read more

- 22 December 2025 News


Middle East countries
Dubai's Mohammed Bin Rashid University of Medicine and Health Sciences introduces new nursing education programmes


Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the learning and discovery arm of Dubai Health, h...Read more

- 22 December 2025 News





All you want to read on

North America Europe Asia Pacific
South East Asia SAARC Middle East



This email has been sent to you in association with
www.biospectrumasia.com
Tell Us What You Think! Help us improve our newsletters.
Send us your feedback!
© Copyright 2025 MM ACTIV. All rights reserved.
To Unsubscribe click here.

Disclaimer : Please remember – by opting-in you are still able to opt-out at any time, by simply replying to this email at digital@mmactiv.com and typing 'unsubscribe' in the 'subject' field of any future emails. We promise only to send emails that we believe you will find interesting, relevant and current.
Your data will never be sold or shared with any third party, although we may communicate a message to you from a partner that we are in collaboration with.